Effect of Trimetazidine on Radiotherapy-induced Heart Damage.
Status:
Not yet recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This is a randomized controlled trial. 80 patients with thoracic radiotherapy will be
included. Participants will be randomly divided into experimental group or control group.
Before radiotherapy, echocardiography, 2D STE, CK, CK-MB, cTnT, NT-proBNP, electrocardiogram
(ECG), and hs-CRP will be detected. During subsequent follow-up, echocardiography, 2D STE,
CK, CK-MB, cTnT, NT-proBNP, ECG, and hs-CRP will be collected at every follow-up time.